Dietary Intake of Vitamin D Is Related to Blood Levels of Advanced Glycation End Products during a Weight Loss Program in Obese Women

Abstract Objectives Advanced Glycation End Products, (AGEs) and their soluble receptor (sRAGE) have been implicated in the development of complications and mortality among individuals with type 2 diabetes (T2D). There is limited information on the relationship between AGEs and sRAGE and risk of cardiovascular diseases (CVD) in minority groups, who have a higher burden of T2D. The relationship between AGEs and sRAGE and CVD risks in adults with T2D and vitamin D insufficiency/deficiency was assessed in a minority population. Methods A cross sectional study of Hispanics and African Americans with T2D (n = 64, 41 women and 23 men, mean age = 54 ± 9) recruited from two clinics in Miami Dade. Systolic (SBP) and diastolic blood pressure (DBP), weight and height measurement and serum lipid profile were completed. ELISA kits were used to assess serum levels of AGEs (Biotang Inc/TSZ Elisa, Waltham, MA, USA) and sRAGE (Biotang Inc/TSZ Elisa, Waltham, MA, USA). Multiple linear regression was used to assess association between AGEs, sRAGE and CVD risks. Results A negative and significant association between AGEs and high-density lipoprotein cholesterol (HDL-C)(B = −0.551, P = 0.029) was found. The relationship between AGEs and HDL-C persisted after adjusting for covariates (P < 0.05). sRAGE was significantly associated with SBP (B = 0.015, P = 0.025) and diastolic blood pressure DBP (B = 0.0271, P = 0.037). Results loss significance when association between sRAGE and DBP and SBP were adjusted for covariates such as age, body mass index (BMI), smoking and alcohol intake. Conclusions Our results suggest that AGEs and sRAGE are related to markers of cardiovascular risk such as HDL-C, SBP and DBP in the study population of African Americans and Hispanics with T2D and vitamin D insufficiency/deficiency. Measures on reducing serum levels of AGEs and improving sRAGE and vitamin D are warranted in these populations for risk reduction of CVD. Funding Sources Partial funding for this research was provided through an NIH/NIDDK sponsored grant.

Download Full-text

Effect of Vaccinium Myrtillus Extract Supplement on Advanced Glycation End-products: A Pilot Study (P06-098-19)

Current Developments in Nutrition ◽

10.1093/cdn/nzz031.p06-098-19 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Cited By ~ 2

Author(s):

Liangkai Chen ◽

Xuguang Zhang ◽

Qiang Wang ◽

Wanyi Li ◽

Liegang Liu

Keyword(s):

Placebo Group ◽

Dietary Intake ◽

Advanced Glycation End Products ◽

Mental State ◽

Intervention Group ◽

Vaccinium Myrtillus ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

Anthropometric Characteristics

Abstract Objectives Excessive consumption of advanced glycation end products (AGEs) with western-style diet in vogue is increasingly seen as a potential cause of aging and metabolic diseases. Several berries contain appreciable quantities of bioactive phytonutrients, including phenolic compounds, which are potentially good candidates as AGE inhibitors. This parallel double-blind intervention study investigated whether the Vaccinium Myrtillus extract supplement is able to reduce the AGEs levels in humans. (clinicaltrials.gov NCT03316612) Methods Seventy-four healthy subjects were randomly assigned to an intervention group (4 tablets per day, containing 600 mg Vaccinium Myrtillus extract, n = 39) versus placebo group (tablets with the same appearance but without the berry extract, n = 35). We evaluated dietary intake, sleep, exercise, mental state, and anthropometric characteristics over the 3 months of intervention. Plasma soluble receptor for AGE (sRAGE) levels were determined by ELISA (R&D). Plasma protein-bound AGEs, including Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL), were determined by ultra-high performance liquid chromatography-tandem mass spectrometry. Results Dietary intake, sleep, exercise, mental state, anthropometric characteristics, and plasma sRAGE levels were not changed during the intervention in two groups. CML levels [1137.5 (918.5–1493.0) vs. 840.9 (757.4–953.8) μg/L, P < 0.001] decreased significantly in the intervention group compared with the placebo group. However, we did not observe a significant change of CEL levels [201.9 (168.5–236.3) vs.176.8 (147.1–212.6) μg/L, P = 0.067] in the intervention group. Conclusions Our results suggest that plasma protein-bound AGEs can be reduced partly by Vaccinium Myrtillus extract supplement. As widely available, safe and nutritious foods, berries with rich phenolic metabolites (particularly anthocyanins) represent a promising dietary intervention worthy of further investigation. Funding Sources Nutrition Scientific Research Foundation of BY-HEALTH. Supporting Tables, Images and/or Graphs

Download Full-text

Advanced glycation end products (AGEs) in metabolic disease: linking diet, inflammation and microbiota

Proceedings of The Nutrition Society ◽

10.1017/s002966512000316x ◽

2020 ◽

Vol 79 (OCE2) ◽

Author(s):

Giulia Gaudioso ◽

Debora Collotta ◽

Fausto Chiazza ◽

Raffaella Mastrocola ◽

Alessia Cento ◽

...

Keyword(s):

Metabolic Disease ◽

Gut Microbiota ◽

Advanced Glycation End Products ◽

Disease Risk ◽

In Vivo Studies ◽

Blood Levels ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

The Impact

AbstractIntroduction:High sugar consumption promotes endogenous formation of advanced glycation end-products (AGEs), a heterogeneous class of molecules originated from non-enzymatic glycation between reducing sugars and free amino groups of proteins, nucleic acids, or lipids. AGEs accumulation in tissues has been linked to aging and diabetes complications. AGEs might also play an independent role in inflammation and development of cardiovascular disease (CVD). Exogenous dietary AGEs, due to excess intake of modern heat-treated foods, might act synergistically with endogenous AGEs, thus contributing to increase inflammation and CVD. A large amount of ingested AGEs reaches the colon, where they might affect gut microbial metabolism, for example, by acting as substrate for colonic bacterial fermentation, driving alterations of microbiota composition and of intestinal permeability. However in vitro and in vivo studies (animal and human) on the impact of AGEs on the gut microbiota are discordant. This study on mice aims to link the modulation of gut microbiota by AGEs-enriched diet (AGE-D) with metabolic and inflammatory markers.Materials and methods:C57BL/6 mice were randomly allocated into the following dietary regimens: Control (n = 24) and AGE-D (n = 20) for 22 weeks. AGE-D was prepared replacing casein (200 g/kg diet) by an equal amount of modified casein where 10% of arginine was glycated with MG-H1 (methylglyoxal 5-hydro-5-methylimidazolone) for a total of 4 μmol of MG-H1 per g of diet. Faeces were collected using metabolic cages (18 h starving) at week 0, 11 and 22 for fecal DNA extraction and 16SrRNA analysis through Illumina MiSeq using V3-V4 targeted primers. After 22 weeks of dietary manipulation, mice were sacrificed, plasma and organ lipid profiles and serum metabolic and inflammatory profiles were determined.Results and discussion:AGE-D caused a significant reduction in the blood levels of two important components of the incretin system, GIP and GLP-1, when compared to control diet, suggestive of unbalance in the incretin-insulin axis. AGE-D exposure was associated with a significant increase in systemic concentrations of inflammatory cytokines, e.g. IL-1β and IL-17, and PAI-1, which has been suggested as both reliable marker and critical mediator of cellular senescence. We will present how AGEs impact on microbiome community structure and correlate changes in gut microbiota with GIP and GLP-1 levels.Conclusions:AGEs, characteristic of modern processed foods, appear to impact on the incretin-insulin axis, a key regulator of metabolic disease risk. Diets rich in AGEs may mediate these physiological effects at least in part, by reshaping intestinal microbiota structure.

Download Full-text

Effect of 4000 IU Vitamin D3 Supplements on Advanced Glycation End Products (AGEs) Among Adults with Type 2 Diabetes and Hypovitaminosis D

Current Developments in Nutrition ◽

10.1093/cdn/nzaa067_056 ◽

2020 ◽

Vol 4 (Supplement_2) ◽

pp. 1829-1829

Author(s):

Justina Owusu ◽

Fatma Huffman ◽

Juan Liuzzi ◽

Sahar Ajabshir ◽

Tan Li ◽

...

Keyword(s):

Vitamin D ◽

Advanced Glycation End Products ◽

Vitamin D3 ◽

Hypovitaminosis D ◽

Mean Difference ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

The Mean ◽

Study Participants

Abstract Objectives Diabetes related complications include kidney, eye, heart diseases and amputations. Advanced Glycation End Products, (AGEs) are biomarkers of T2D. AGEs are covalent adducts formed from reactions between sugars and proteins or lipids. Vitamin D deficiency, prevalent with T2D, increases oxidative stress and inflammation that promotes the formation of AGEs. This study assessed the effect of 4000 IU vitamin D supplements on AGEs in adults with T2D and vitamin D deficiency/insufficiency. Methods We assessed changes in serum AGEs of 41 African Americans and Hispanics with T2D and hypovitaminosis D who were supplemented with 4000 IU of vitamin D3 for 6 months. Total AGEs were assessed using commercially available kits (Biotang Inc/TSZ Elisa, Waltham, MA, USA). Results The mean age of study participants was 54 ± 8 years. AGEs significantly increased at 3 months compared to baseline (Mean Difference = −13.70 ng/ml, P = 0.007). The mean level of AGEs decreased significantly at 6 months of supplementation (Mean Difference = 9.79 ng/ml, P = 0.020). Additionally, the mean serum levels of AGEs were significantly higher at 3 months compared to 6 months among study participants (Mean Difference = 24.52 ng/ml, P < 0.0001). Conclusions Daily supplementation of 4000 IU vitamin D3 reduced AGEs at 6 months but not at 3 months. Supplementation of this minority population with vitamin D may delay the accumulation of AGEs and complications related to T2D. Funding Sources Funding for this research was provided through an NIH/NIDDK sponsored grant.

Download Full-text

The effects of vitamin D on advanced glycation end-products in prediabetic and type 2 diabetic patients with vitamin D deficiency

Endocrine Abstracts ◽

10.1530/endoabs.41.ep547 ◽

2016 ◽

Author(s):

Bahar Tekin ◽

F. Buket Bayram ◽

Dilek Gogas Yavuz

Keyword(s):

Vitamin D ◽

Vitamin D Deficiency ◽

Advanced Glycation End Products ◽

Diabetic Patients ◽

Advanced Glycation ◽

Type 2 Diabetic Patients ◽

Glycation End Products ◽

End Products ◽

Type 2 Diabetic

Download Full-text

Leptin and advanced glycation end products receptor (RAGE) in tuberculosis patients

PLoS ONE ◽

10.1371/journal.pone.0254198 ◽

2021 ◽

Vol 16 (7) ◽

pp. e0254198

Author(s):

Tássia Kirchmann Lazzari ◽

Erika Cavalheiro ◽

Sandra Eugênia Coutinho ◽

Lívia Fontes da Silva ◽

Denise Rossato Silva

Keyword(s):

Weight Loss ◽

Advanced Glycation End Products ◽

Inverse Correlation ◽

Advanced Glycation ◽

Serum Leptin ◽

Soluble Rage ◽

Glycation End Products ◽

End Products ◽

Carboxymethyl Lysine ◽

Control Study

Introduction The pathogenesis of consumptive syndrome of tuberculosis (TB) is largely unknown. Leptin concentrations may be high because of the host’s inflammatory response, contributing to weight loss in patients with TB. The receptor for advanced glycation end products (RAGE) is also associated with weight loss in patients with TB and is related to enhanced mortality. The objective of this study was to evaluate the association between leptin and AGE/RAGE. Methods Case-control study. Leptin, AGE (carboxymethyl lysine, CML) and soluble RAGE (sRAGE) were measured from blood samples by ELISA. Results We included in the study 34 patients with TB and 34 controls. We found an inverse correlation between serum leptin levels and sRAGE, only in cases (r = -0.609, p < 0.0001). sRAGE levels were lower in patients with TB who died as compared with patients who survive (21.90 ± 4.24 pg/mL vs 66.14 ± 29.49 pg/mL; p = 0.045). Leptin levels were higher in patients with TB who died as compared with patients who survive (14.11 [7.48–14.11] ng/mL vs 3.08 [0.54–6.34] ng/mL; p = 0.028). Conclusions We identified lower sRAGE levels and higher leptin levels in patients with TB who died as compared with patients who survive. In addition, an inverse and significant correlation between serum leptin and sRAGE levels was demonstrated. Future studies, with a larger sample size and in different settings, including not only hospitalized patients, are needed to confirm these findings.

Download Full-text